Clinical Trials Logo

Clinical Trial Summary

To evaluate the diagnostic performance (primary) and safety (secondary) of seven T.R.U.E. Test Panel 3.2 allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol in pediatric subjects 6-18 years of age with suspected contact dermatitis based on symptoms and clinical history.


Clinical Trial Description

The study population will include at least 100 consecutive subjects 6-17 years of age with suspected contact dermatitis based on symptoms and clinical history. Study subjects must be otherwise healthy and fulfill entry criteria.

Visit 1 (Day 0): Informed Consent, Inclusion/Exclusion Criteria Assessment, Medical and Medicine History, Pregnancy Test (for female subjects of child-bearing potential), Panel Placement.Visit 2 (Day 2): Panel Removal, Panel Adhesion and Irritation Assessment, AE and Concomitant Medication Review.Visit 3 (Day 3- approximately 72 hours after placement): Skin Reactions Assessed and Scored. Adverse Event and Concomitant Medication Review.Visit 4 (Day 4 approximately 96 hours after placement): Skin Reactions Assessed and Scored. Adverse Event and Concomitant Medication Review.Visit 5 (Day 7±1): Skin Reaction Assessed and Scored. AE and Concomitant Medication Review. Visit 6 (Day 21±2): Skin Reaction Assessed and Scored. AE and Concomitant Medication Review. Visit performed via phone call, unless investigator determines that subject should be seen in clinic.

Primary Endpoint: Frequency and characterization of positive reactions per allergen. Secondary Endpoint: Prevalence of late or persistent reactions, irritation, adhesion, subject-reported itching or burning, and adverse events. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT01518348
Study type Interventional
Source Allerderm
Contact
Status Withdrawn
Phase Phase 3
Start date December 2012
Completion date December 2013

See also
  Status Clinical Trial Phase
Completed NCT00371163 - Molecular and Cellular Characterization of Spongiotic Dermatitis N/A
Completed NCT02028208 - Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study Phase 2
Not yet recruiting NCT04853823 - A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB Phase 1
Completed NCT02700373 - A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers Phase 1
Completed NCT03089775 - Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis Phase 1
Completed NCT04438135 - Children With Aluminium Contact Allergy: Cutaneous Exposure Study N/A
Recruiting NCT06189144 - Testing an Intervention in Irritative Contact Dermatitis N/A
Completed NCT04921163 - Children With Aluminium Contact Allergy: Oral Exposure Study N/A
Not yet recruiting NCT02026700 - Bariederm Cream in Chronic Contact Dermatitis N/A
Completed NCT02028182 - Clinical Evaluation of Lyral® Dose Response Study Phase 2
Completed NCT00824889 - Exploratory Study of Natural Killer Cells in Human Skin N/A
Completed NCT00646867 - Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis N/A
Recruiting NCT03705182 - Prevention of Dermatitis in Epoxy Exposed Workers N/A
Terminated NCT03198390 - Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions
Completed NCT00614289 - Novel Topical Treatment of Hand Dermatitis (Eczema) Phase 1
Recruiting NCT06331390 - Assessment of Niacinamide Cosmetic Product Efficacy in Model of Irritant Contact Dermatitis N/A
Completed NCT00640614 - Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy Phase 3
Completed NCT00640250 - Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response Phase 2
Recruiting NCT06177314 - Molecular Diagnosis of Allergic Contact Dermatitis
Completed NCT04772482 - Study on Hypoallergenic Hair Dye